Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia

被引:19
|
作者
Hatta, Kotaro [1 ,15 ]
Otachi, Taro [2 ]
Fujita, Kiyoshi [3 ]
Morikawa, Fumiyoshi [4 ]
Ito, Shin [5 ]
Tomiyama, Hirofumi [6 ]
Abe, Takayuki [7 ]
Sudo, Yasuhiko [8 ]
Takebayashi, Hiroshi [9 ]
Yamashita, Toru [10 ]
Katayama, Shigemasa [11 ]
Nakase, Reiko [12 ]
Shirai, Yutaka [13 ]
Usui, Chie [1 ]
Nakamura, Hiroyuki [14 ]
Ito, Hiroto [15 ]
Hirata, Toyoaki [7 ]
Sawa, Yutaka [16 ]
机构
[1] Juntendo Univ, Dept Psychiat, Nerima Hosp, Tokyo 1778521, Japan
[2] Gunma Psychiat Med Ctr, Dept Psychiat, Isesaki, Japan
[3] Okehazama Hosp, Dept Psychiat, Toyoake, Aichi, Japan
[4] Asahikawa Keisenkai Hosp, Dept Psychiat, Asahikawa, Hokkaido, Japan
[5] Kumpukai Yamada Hosp, Dept Psychiat, Tokyo, Japan
[6] Natl Hosp Org Hizen Psychiat Ctr, Dept Psychiat, Yoshinogari, Japan
[7] Chiba Psychiat Med Ctr, Dept Psychiat, Chiba, Japan
[8] Tosa Hosp, Dept Psychiat, Kochi, Japan
[9] Saitama Prefectural Psychiat Hosp, Dept Psychiat, Ina, Saitama, Japan
[10] Yamanashi Prefectural Kita Hosp, Dept Psychiat, Nirasaki, Japan
[11] Seijin Hosp, Dept Psychiat, Tokyo, Japan
[12] Mie Prefectural Mental Med Ctr, Dept Psychiat, Tsu, Mie, Japan
[13] Hyogo Prefecture Kofu Hosp, Dept Psychiat, Kobe, Hyogo, Japan
[14] Kanazawa Univ, Dept Environm & Prevent Med, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan
[15] Natl Ctr Neurol & Psychiat, Dept Social Psychiat, Kodaira, Tokyo, Japan
[16] Sawa Hosp, Dept Psychiat, Osaka, Japan
关键词
Early response; Combination; Add-on; Polypharmacy; Emergency; Randomized clinical trial; PHARMACOKINETICS; MEDICATIONS; MONOTHERAPY; SCALE;
D O I
10.1016/j.schres.2014.07.015
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose: We examined whether augmentation with olanzapine would be superior to switching to olanzapine among early non-responders (ENRs) to risperidone, and whether augmentation with risperidone would be superior to switching to risperidone among ENRs to olanzapine. We performed a rater-blinded, randomized clinical trial at psychiatric emergency sites. Eligible patients were newly admitted patients with acute schizophrenia. ENRs to the initial antipsychotic (Clinical Global Impressions-Improvement Scale: >= 4 at 2 weeks) were allocated to receive either augmentation with or switching to the other antipsychotic (RIS + OLZ vs. RIS-OLZ; OLZ + RIS vs. OLZ-RIS). Results: Sixty patients who completed 2 weeks of risperidone treatment were divided into 33 early responders (RIS-ER) and 27 ENRs (RIS + OLZ, n = 14; RIS-OLZ, n = 13). Although time to treatment discontinuation for any cause was significantly shorter in RIS + OLZ group (54.1 days [95% confidence interval, 41.3-67.0]) than in RIS-ER group (68.7 [61.2-76.2]; P = 0.050), it was not significantly shorter in RIS-OLZ group (58.5 [43.1-73.9]) than in RIS-ER group (P = 0.19). Sixty patients who completed 2 weeks of olanzapine treatment were divided into 36 early responders (OLZ-ER) and 24 ENRs (OLZ + RIS, n = 11; OLZ-RIS, n = 13). Although time to treatment discontinuation for any cause was significantly shorter in OLZ-RIS group (56.1 days [40.7-71.5]) than in OLZ-ER group (74.9 [68.5-81.3]; P = 0.008), it was not significantly shorter in OLZ + RIS group (64.6 [49.6-79.6]) than in OLZ-ER group (P= 0.20). Conclusion: Despite the lack of pharmacokinetic investigation of dose adequacy in this study, it is possible that switching to olanzapine among ENRs to risperidone might have a small advantage over augmentation with olanzapine, while augmentation with risperidone might have a small advantage over switching to risperidone among ENRs to olanzapine. Further research is required before itwould be appropriate tomodify routine practice in the direction of these findings. (C) 2014 The Authors. Published by Elsevier B. V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
引用
收藏
页码:213 / 222
页数:10
相关论文
共 7 条
  • [1] Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia
    Hatta, Kotaro
    Otachi, Taro
    Sudo, Yasuhiko
    Hayakawa, Tatsuro
    Ashizawa, Yuko
    Takebayashi, Hiroshi
    Hayashi, Naoki
    Hamakawa, Hiroshi
    Ito, Shin
    Nakase, Reiko
    Usui, Chie
    Nakamura, Hiroyuki
    Hirata, Toyoaki
    Sawa, Yutaka
    [J]. SCHIZOPHRENIA RESEARCH, 2011, 128 (1-3) : 127 - 135
  • [2] Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy
    Hatta, Kotaro
    Sugiyama, Naoya
    Ito, Hiroto
    [J]. THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2018, 8 (06) : 173 - 183
  • [3] THE COST-EFFECTVENESS OF EARLY RESPONDERS VERSUS EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTIC THERAPY
    Peng, X.
    Ascher-Svanum, H.
    Faries, D.
    Stauffer, V. L.
    Kollack-Walker, S.
    Kinon, B. J.
    Kane, J. M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A113 - A114
  • [4] Switching schizophrenia patients previously stable on chronic conventional antipsychotic therapy to risperidone versus olanzapine
    Wang, XH
    Savage, R
    Borisov, A
    Rosenberg, J
    Woolwine, B
    Peelor, M
    May, R
    Feldman, J
    Miller, AH
    [J]. NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S175 - S175
  • [5] A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone
    Hatta, Kotaro
    Otachi, Taro
    Sudo, Yasuhiko
    Kuga, Hironori
    Takebayashi, Hiroshi
    Hayashi, Hideaki
    Ishii, Ryusuke
    Kasuya, Masataka
    Hayakawa, Tatsuro
    Morikawa, Fumiyoshi
    Hata, Kazuya
    Nakamura, Mitsuru
    Usui, Chie
    Nakamura, Hiroyuki
    Hirata, Toyoaki
    Sawa, Yutaka
    [J]. PSYCHIATRY RESEARCH, 2012, 198 (02) : 194 - 201
  • [6] Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia
    Hatta, Kotaro
    Ito, Hiroto
    [J]. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2014, 12 (01) : 1 - 7
  • [7] An open study of olanzapine versus risperidone in the management of early-phase schizophrenia and related disorders
    van Bruggen, JM
    Linszen, DH
    Dingemans, PM
    [J]. SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 316 - 317